JP Morgan Maintains Neutral on 10x Genomics, Lowers Price Target to $9

Benzinga · 05/09 21:04
JP Morgan analyst Rachel Vatnsdal maintains 10x Genomics (NASDAQ:TXG) with a Neutral and lowers the price target from $12 to $9.